RBC Capital raised their price target on shares of Medicines (NASDAQ:MDCO) from $41.00 to $50.00 in a research note issued on Thursday, Stock Ratings News reports. The firm currently has an “outperform” rating on the stock. RBC Capital’s price objective indicates a potential upside of 32.63% from the company’s current price.
A number of other analysts have also recently weighed in on MDCO. Analysts at Zacks reiterated a “neutral” rating on shares of Medicines in a research note to investors on Thursday, November 28th. They now have a $38.00 price target on the stock. Separately, analysts at Leerink Swann reiterated an “outperform” rating on shares of Medicines in a research note to investors on Thursday, October 10th. They now have a $42.00 price target on the stock, up previously from $40.00. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $38.05.
Medicines (NASDAQ:MDCO) opened at 37.70 on Thursday. Medicines has a 1-year low of $21.39 and a 1-year high of $38.52. The stock’s 50-day moving average is $35.6 and its 200-day moving average is $33.11. The company has a market cap of $2.233 billion and a P/E ratio of 60.92.
Medicines (NASDAQ:MDCO) last issued its quarterly earnings data on Wednesday, October 23rd. The company reported $0.47 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.24 by $0.23. The company had revenue of $173.45 million for the quarter, compared to the consensus estimate of $173.86 million. During the same quarter last year, the company posted $0.40 earnings per share. Medicines’s revenue was up 27.4% compared to the same quarter last year. On average, analysts predict that Medicines will post $0.41 earnings per share for the current fiscal year.
In other Medicines news, CEO Clive Meanwell unloaded 10,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $36.58, for a total value of $365,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
The Medicines Company is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.